Status:

TERMINATED

Connected Catheter- Safety and Effectiveness Study

Lead Sponsor:

Spinal Singularity

Conditions:

Urinary Retention

Neurogenic Bladder

Eligibility:

MALE

18+ years

Phase:

NA

Brief Summary

The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. It is a...

Detailed Description

Spinal Singularity has developed the Connected Catheter System to address several drawbacks of urinary catheters. The Connected Catheter is fully internal, indwelling urinary prosthesis designed for i...

Eligibility Criteria

Inclusion

  • Males age ≥ 18 with clinical diagnosis of significant urinary retention
  • Must be clinically suitable and capable of safely managing bladder using an intermittent voiding or indwelling strategy
  • Must have stable urinary management history as determined by the Investigator
  • OR:
  • Must have urodynamic profile suitable for the Gen 2 Connected Catheter (including bladder capacity \> 200mL without uninhibited bladder contractions)
  • Subject's lower urinary tract anatomy must fall within the ranges serviceable by the Gen 2 Connected Catheter device, as specified in the Investigational Device Instructions for use (IFU)

Exclusion

  • Active symptomatic urinary tract infection (UTI), as defined in this protocol (subjects may receive the device after UTI has been treated)
  • Significant risk profile or recent history of urethral stricture (e.g. stricture within past 90 days)
  • Significant risk profile or recent history of clinically significant (uncontrolled) autonomic dysreflexia (AD)
  • Significant intermittent urinary incontinence (between catheterizations)
  • Uninhibited bladder contractions and/or Vesicoureteral reflux that is not reliably controlled with medication or alternate therapy (e.g. Botox injections)
  • Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy and urine analysis)
  • Urinary tract inflammation or neoplasm
  • Urinary fistula
  • Bladder diverticulum (outpouching) \> 5cm in size
  • Chronic pyelonephritis (secondary to upper urinary tract infection(s) within past 6 months)
  • Impaired kidney function or renal failure
  • Active gross hematuria
  • Active urethritis
  • Bladder stones
  • Dependence on an electro-magnetic medical implant (e.g. cardiac pacemaker or implanted drug pump) or external device
  • Any unsuitable comorbidities as determined by the investigator or complications related to use of certain medications
  • Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the Connected Catheter System
  • Catheter Assessment Tool screening yields unacceptable results

Key Trial Info

Start Date :

October 16 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 6 2021

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT03843073

Start Date

October 16 2020

End Date

April 6 2021

Last Update

November 23 2021

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

West Coast Urology, 11411 Brookshire Avenue, Suite 508

Downey, California, United States, 90241

2

West Coast Urology, 575 E. Hardy St., Suite 215

Inglewood, California, United States, 90301

3

Tri Valley Urology, 25495 Medical Center Dr., Suite 204

Murrieta, California, United States, 92562

4

Chesapeake Urology

Owings Mills, Maryland, United States, 21117